OS Therapies Net Income Over Time
| OSTX Stock | 1.20 0.03 2.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out OS Therapies Performance and OS Therapies Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OS Therapies. Anticipated expansion of OSTX directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive OS Therapies assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of OS Therapies is measured differently than its book value, which is the value of OSTX that is recorded on the company's balance sheet. Investors also form their own opinion of OS Therapies' value that differs from its market value or its book value, called intrinsic value, which is OS Therapies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OS Therapies' market value can be influenced by many factors that don't directly affect OS Therapies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between OS Therapies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OS Therapies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, OS Therapies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare OS Therapies and related stocks such as Spruce Biosciences Common, Werewolf Therapeutics, and OUTLOOK THERAPEUTICS INC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRB | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (13.2 M) | (29.5 M) | (42.3 M) | (46.2 M) | (47.9 M) | (53 M) | (47.7 M) | (50.1 M) |
| HOWL | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (14.9 M) | (49.8 M) | (51.6 M) | (37.4 M) | (70.5 M) | (63.5 M) | (60.3 M) |
| OTLK | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (47.4 M) | (53.3 M) | (38.8 M) | (30.1 M) | (34.5 M) | (35.2 M) | (53.2 M) | (66.1 M) | (59 M) | (75.4 M) | (62.4 M) | (56.2 M) | (59 M) |
| IOBT | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (12 M) | (67.9 M) | (71.5 M) | (86.1 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| CRVO | 200 K | (22.6 M) | (6.9 M) | (2.5 M) | (14.4 M) | (6.7 M) | (18 M) | (1.4 M) | (18.4 M) | (11.8 M) | (14.2 M) | (24.1 M) | (15.6 M) | (2.2 M) | (16.3 M) | (14.7 M) | (13.9 M) |
| INKT | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (16.2 M) | (30.2 M) | (28 M) | (22.5 M) | (10.8 M) | (12.4 M) | (13 M) |
| EQ | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (13.2 M) | (25.6 M) | (29.8 M) | (39 M) | (62.4 M) | (13.3 M) | (8.1 M) | (7.3 M) | (7.6 M) |
| COEP | 2.6 M | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (2.2 K) | (9.2 M) | (13.4 M) | (37.6 M) | (21.3 M) | (10.9 M) | (9.8 M) | (10.3 M) |
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (33.4 M) | (30.1 M) | (31.6 M) |
| NRXP | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | 66.1 K | 408.4 K | (51.8 M) | (93.1 M) | (39.8 M) | (30.1 M) | (25.1 M) | (22.6 M) | (23.7 M) |
OS Therapies and related stocks such as Spruce Biosciences Common, Werewolf Therapeutics, and OUTLOOK THERAPEUTICS INC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in OS Therapies financial statement analysis. It represents the amount of money remaining after all of OS Therapies Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| OS Therapies Incorporated | OSTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 115 Pullman Crossing |
| Exchange | NYSE MKT Exchange |
null 1.2
Additional Tools for OSTX Stock Analysis
When running OS Therapies' price analysis, check to measure OS Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OS Therapies is operating at the current time. Most of OS Therapies' value examination focuses on studying past and present price action to predict the probability of OS Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OS Therapies' price. Additionally, you may evaluate how the addition of OS Therapies to your portfolios can decrease your overall portfolio volatility.